malondialdehyde has been researched along with exenatide in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 11 (78.57) | 24.3611 |
| 2020's | 3 (21.43) | 2.80 |
| Authors | Studies |
|---|---|
| Bunck, MC; Cornér, A; Diamant, M; Eliasson, B; Heine, RJ; Shaginian, RM; Smith, U; Taskinen, MR; Wu, Y; Yan, P; Yki-Järvinen, H | 1 |
| Cai, Y; Hu, X; Wen, Z; Yi, B; Zhang, T | 1 |
| Hu, G; Hu, X; Jiang, H; Zhang, Y | 1 |
| Chang, G; Duan, Q; Liu, J; Lu, K; Qin, S; Ye, L; Zhang, D; Zhang, P; Zheng, A | 1 |
| Akseki, HS; Aktuğ, H; Erbaş, O; Solmaz, V; Taşkıran, D | 1 |
| Artunc-Ulkumen, B; Erbas, O; Pala, EE; Pala, HG; Yavasoglu, A; Yigitturk, G | 1 |
| He, M; Li, S; Niu, S; Peng, Y; Wang, L | 1 |
| Bołdys, A; Bułdak, RJ; Bułdak, Ł; Machnik, G; Okopień, B; Łabuzek, K | 1 |
| Fan, Z; Jia, Z; Li, G; Li, H; Lv, G; Sun, P; Wang, J; Zhao, X | 1 |
| Abdelwahed, OM; Gamal El Din, MM; Rashed, L; Tork, OM; Zickri, M | 1 |
| Han, C; Li, J; Li, S; Liu, X; Ma, Y; Wang, X; Zhang, J; Zhang, L; Zheng, L | 1 |
| Cui, J; Cui, R; Li, H; Lu, D; Tian, L | 1 |
| Ma, A; Wang, T; Wang, Y; Wei, X; Yang, Y; Zhou, Y | 1 |
| Bayraktaroğlu, T; Ergenc, M; Ozacmak, VH; Sayan Ozacmak, H; Turan, I | 1 |
1 trial(s) available for malondialdehyde and exenatide
| Article | Year |
|---|---|
One-year treatment with exenatide vs. insulin glargine: effects on postprandial glycemia, lipid profiles, and oxidative stress.
Topics: Apolipoprotein B-48; Biomarkers; Blood Glucose; Cholesterol, VLDL; Diabetes Mellitus, Type 2; Drug Administration Schedule; Europe; Exenatide; Fatty Acids, Nonesterified; Female; Glycated Hemoglobin; Humans; Hyperlipidemias; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Lipids; Lipoproteins, LDL; Male; Malondialdehyde; Middle Aged; Oxidative Stress; Peptides; Postprandial Period; Time Factors; Treatment Outcome; Triglycerides; Venoms | 2010 |
13 other study(ies) available for malondialdehyde and exenatide
| Article | Year |
|---|---|
Glucagon-like peptide-1 receptor agonist protects against hyperglycemia-induced cardiocytes injury by inhibiting high mobility group box 1 expression.
Topics: Animals; Creatine Kinase; Cytoprotection; Exenatide; Glucagon-Like Peptide-1 Receptor; HMGB1 Protein; Hyperglycemia; Interleukin-1beta; L-Lactate Dehydrogenase; Malondialdehyde; Myocytes, Cardiac; Peptides; Rats; Rats, Sprague-Dawley; Receptors, Glucagon; Superoxide Dismutase; Tumor Necrosis Factor-alpha; Venoms | 2012 |
Exendin-4 attenuates myocardial ischemia and reperfusion injury by inhibiting high mobility group box 1 protein expression.
Topics: Animals; Creatine Kinase; Cytoprotection; Disease Models, Animal; Down-Regulation; Exenatide; Glucagon-Like Peptide-1 Receptor; HMGB1 Protein; L-Lactate Dehydrogenase; Male; Malondialdehyde; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium; Peptide Fragments; Peptides; Rats; Rats, Sprague-Dawley; Receptors, Glucagon; Superoxide Dismutase; Time Factors; Venoms | 2013 |
Exenatide protects against hypoxia/reoxygenation-induced apoptosis by improving mitochondrial function in H9c2 cells.
Topics: Animals; Antioxidants; Apoptosis; Caspase 3; Cell Hypoxia; Cell Line; Cytochromes c; Exenatide; Flow Cytometry; Glucagon-Like Peptide 1; Malondialdehyde; Membrane Potential, Mitochondrial; Mitochondria; Myocytes, Cardiac; Oxidative Stress; Peptides; Rats; Superoxide Dismutase; Venoms | 2014 |
Fatty liver-induced changes in stereotypic behavior in rats and effects of glucagon-like peptide-1 analog on stereotypy.
Topics: Animals; Brain; Exenatide; Fatty Liver; Glucagon-Like Peptide 1; Liver; Male; Malondialdehyde; Peptides; Rats, Sprague-Dawley; Stereotyped Behavior; Tumor Necrosis Factor-alpha; Venoms | 2014 |
Exenatide improves ovarian and endometrial injury and preserves ovarian reserve in streptozocin induced diabetic rats.
Topics: Animals; Anti-Mullerian Hormone; C-Reactive Protein; Diabetes Mellitus, Experimental; Endometrium; Exenatide; Female; Inflammation; Lipid Peroxidation; Malondialdehyde; Ovarian Reserve; Ovary; Oxidative Stress; Peptides; Rats; Rats, Sprague-Dawley; Serum Amyloid P-Component; Transforming Growth Factor beta; Venoms | 2015 |
Exendin-4 regulates redox homeostasis in rats fed with high-fat diet.
Topics: Animals; Cystathionine beta-Synthase; Diet, High-Fat; Down-Regulation; Exenatide; Glutathione; Homeostasis; Homocysteine; Male; Malondialdehyde; Non-alcoholic Fatty Liver Disease; Oxidation-Reduction; Peptides; Rats; Rats, Sprague-Dawley; RNA, Messenger; Venoms | 2015 |
Exenatide (a GLP-1 agonist) improves the antioxidative potential of in vitro cultured human monocytes/macrophages.
Topics: Adolescent; Adult; Antioxidants; Cells, Cultured; Exenatide; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Lipopolysaccharides; Macrophages; Male; Malondialdehyde; Monocytes; Oxidation-Reduction; Oxidative Stress; Peptides; Reactive Oxygen Species; Superoxide Dismutase; Venoms; Young Adult | 2015 |
Neuroprotective effects of exendin-4 in rat model of spinal cord injury via inhibiting mitochondrial apoptotic pathway.
Topics: Animals; Apoptosis; Exenatide; Female; Glutathione; Malondialdehyde; Mitochondria; Models, Animal; Neuroprotective Agents; Oxidative Stress; Peptides; Rats; Rats, Sprague-Dawley; Spinal Cord Injuries; Venoms | 2015 |
Effect of glucagon-like peptide-1 analogue; Exendin-4, on cognitive functions in type 2 diabetes mellitus; possible modulation of brain derived neurotrophic factor and brain Visfatin.
Topics: Animals; Anti-Obesity Agents; Brain; Brain-Derived Neurotrophic Factor; Cognition Disorders; Diabetes Mellitus, Type 2; Disease Models, Animal; Exenatide; Male; Malondialdehyde; Nicotinamide Phosphoribosyltransferase; Rats; Rats, Wistar; Tumor Necrosis Factor-alpha | 2018 |
Exenatide ameliorates hepatic steatosis and attenuates fat mass and FTO gene expression through PI3K signaling pathway in nonalcoholic fatty liver disease.
Topics: Alpha-Ketoglutarate-Dependent Dioxygenase FTO; Animals; Blood Glucose; Body Weight; Chromones; Diet, High-Fat; Disease Models, Animal; Eating; Enzyme Inhibitors; Exenatide; Fatty Liver; Gene Expression Regulation; In Vitro Techniques; Insulin; Male; Malondialdehyde; Morpholines; Non-alcoholic Fatty Liver Disease; Obesity; Oxidative Stress; Peptides; Phosphatidylinositol 3-Kinases; Protective Agents; Rabbits; Superoxide Dismutase; Venoms | 2018 |
Exendin-4 Protects Human Retinal Pigment Epithelial Cells from H2O2-Induced Oxidative Damage via Activation of NRF2 Signaling.
Topics: Blotting, Western; Cell Survival; Cells, Cultured; Exenatide; Glutathione Peroxidase; Heme Oxygenase-1; Humans; Hydrogen Peroxide; Hypoglycemic Agents; Malondialdehyde; NAD(P)H Dehydrogenase (Quinone); NF-E2-Related Factor 2; Oxidants; Oxidative Stress; Protective Agents; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; Retinal Pigment Epithelium; Signal Transduction; Superoxide Dismutase | 2020 |
Exendin-4 regulates endoplasmic reticulum stress to protect endothelial progenitor cells from high-glucose damage.
Topics: Animals; Apoptosis; Body Weight; Cell Survival; Cells, Cultured; Diabetes Mellitus, Experimental; Endoplasmic Reticulum Stress; Endothelial Progenitor Cells; Exenatide; Glucose; Male; Malondialdehyde; MAP Kinase Signaling System; Mice; Mice, Inbred C57BL; Reactive Oxygen Species; Superoxide Dismutase | 2020 |
The effects of glucagon-like peptide 1 receptor agonist (exenatide) on memory impairment, and anxiety- and depression-like behavior induced by REM sleep deprivation.
Topics: Animals; Antioxidants; Anxiety; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Depression; Disks Large Homolog 4 Protein; Exenatide; Glucagon-Like Peptide-1 Receptor; Glutathione; Male; Malondialdehyde; Memory Disorders; Psychomotor Performance; Rats; Rats, Wistar; Sleep Deprivation; Sleep, REM; Swimming | 2021 |